Article

Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in Drug Trials


Drug Trials

Biogen’s Drug BAN2401 Brings in Fresh Hope for Alzheimer’s Treatment

Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply